Immunotherapy for biochemically recurrent prostate cancer.
Ravi A. Madan(National Cancer Institute), James L. Gulley(National Cancer Institute), Julius Strauss(National Cancer Institute), Susan F. Slovin(Cornell University), Amy Hankin(National Institutes of Health), Marijo Bilušić(National Institutes of Health), Lauren C. Harshman(Dana-Farber Cancer Institute), Philip W. Kantoff(Convergent Science (United States)), Jeffrey Schlom(National Cancer Institute), Fatima Karzai(National Institutes of Health), Marc R. Theoret(United States Food and Drug Administration), Philip M. Arlen(Dana-Farber Cancer Institute), Anna Couvillon(National Institutes of Health), Myrna Rauckhorst(National Institutes of Health), Monique Williams(National Institutes of Health), William L. Dahut(National Cancer Institute)
Cited by 6
Related Papers
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
|New England Journal of Medicine|2010|5.5k
Gene expression correlates of clinical prostate cancer behavior
|Cancer Cell|2002|2.5k
Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy
|The Journal of Experimental Medicine|2006|1.7k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k